Pirfenidone

證據等級: L5

預測適應症: 10 個

Pirfenidone: From Idiopathic Pulmonary Fibrosis to Extracutaneous Mastocytoma

One-Sentence Summary

Pirfenidone is an antifibrotic agent whose established clinical use — per literature citation (PMID 29702057) — is idiopathic pulmonary fibrosis (IPF); no official regulatory indication text is available in this dataset. The TxGNN model's top prediction is Extracutaneous Mastocytoma, but this candidate is currently supported by zero clinical trials and zero publications — the score reflects a pure knowledge-graph prediction with no external validation.

⚠️ Note: All 10 predicted indications in this evidence pack are rated L5 (model prediction only) except rank 9 (fibroblastic neoplasm), which reached L4 — driven mainly by negative safety signals (case reports of sarcoma occurrence and dermatofibroma aggravation), not positive efficacy evidence.

Quick Overview

Item	Content
Original Indication	Idiopathic Pulmonary Fibrosis (IPF) — sourced from literature citation only; official regulatory indication text not available (data gap)
Predicted New Indication	Extracutaneous Mastocytoma
TxGNN Prediction Score	99.71%
Evidence Level	L5
Germany Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (original_moa: [Data Gap]). Based on external literature embedded in this evidence pack, pirfenidone is known to inhibit TGF-β1–mediated signalling (including non-SMAD pathways), reduce fibroblast proliferation, and decrease collagen deposition — a mechanism well-documented for fibrotic disorders such as IPF and Dupuytren's disease.

For the top-ranked candidate, extracutaneous mastocytoma, this mechanism does not map cleanly onto the disease biology. Mastocytoma is driven by mast cell proliferation (often KIT-pathway related), not by fibroblast/TGF-β–mediated fibrosis. The evidence pack's own rationale explicitly flags this as a "weak, purely inferential" link, likely reflecting graph-embedding proximity between fibrosis-related and mast-cell-related nodes rather than a genuine pharmacological relationship.

Notably, among the ten predictions, most (mastocytoma, fibrosarcoma subtypes, dermatofibrosarcoma protuberans) cluster around a "TGF-β/anti-fibroblast" hypothesis for soft-tissue neoplasms. However, the only prediction with actual literature support (rank 9, fibroblastic neoplasm) surfaces a safety concern in the opposite direction — case reports of pirfenidone-associated undifferentiated pleomorphic sarcoma and aggravated dermatofibroma — which undermines the "anti-fibrotic = anti-tumour" assumption underlying several of these predictions.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top-ranked indication (Extracutaneous Mastocytoma).

(Note: literature evidence exists only for rank 9 — Fibroblastic Neoplasm — see Safety Considerations below.)

Germany Market Information

Pirfenidone currently has no marketing authorizations on record in this dataset (total_licenses: 0). No product/dosage-form information is available.

Safety Considerations

All primary safety fields (key warnings, contraindications, DDI) are marked as data gaps in this dataset:

Please refer to the package insert for safety information.

Notable literature-derived safety signal (from evidence tied to a lower-ranked prediction, not from formal safety data):

A case report describes undifferentiated pleomorphic sarcoma occurring after pirfenidone use (PMID 29702057).
A separate case report describes aggravation of multiple eruptive dermatofibromas in a patient on pirfenidone + mycophenolate mofetil (PMID 32572469).

These are isolated case reports, not causally established, but they warrant caution before pursuing any fibroblastic/soft-tissue-neoplasm-related repurposing hypothesis for this drug.

Conclusion and Next Steps

Decision: Hold

Rationale: Every predicted indication in this evidence pack is either unsupported by any clinical trial or literature (L5), or supported only by literature that raises a safety concern rather than efficacy evidence (L4, rank 9). Combined with missing MOA data, missing regulatory/safety documentation, and zero market authorizations, there is currently no basis to advance any candidate beyond model-prediction stage.

To proceed, the following is needed:

TFDA/BfArM package insert (warnings, contraindications) — currently blocking (DG001)
Confirmed MOA from DrugBank API — currently high-severity gap (DG002)
Confirmed original indication and regulatory approval text (currently absent from taiwan_regulatory.licenses)
Preclinical or clinical evidence specifically for extracutaneous mastocytoma before any further evaluation
Clarification of the sarcoma-occurrence/dermatofibroma-aggravation safety signal before pursuing any fibroblastic-neoplasm-family indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.